We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Routine Blood Markers Predict Heart Failure Risk in Prediabetes

By LabMedica International staff writers
Posted on 19 Mar 2026

Heart failure prevention relies on finding high-risk adults before symptoms appear, yet effective stratification remains difficult in routine care. More...

Prediabetes affects an estimated 115.2 million U.S. adults as of January 2026 and is broadly linked to cardiovascular complications. Coexisting hypertension and silent cardiac injury or stress further complicate risk assessment. A new study shows that common blood biomarkers can identify a subgroup with markedly elevated risk of heart failure.

Researchers at Johns Hopkins Medicine (Baltimore, MD, USA) led an analysis demonstrating that elevated high-sensitivity cardiac troponin I (hs-cTnI) or N-terminal pro–B-type natriuretic peptide (NT-proBNP) identifies adults with both prediabetes and hypertension who face substantially higher risk of heart failure (HF). The work, published in JAMA Cardiology on January 14, highlights a readily accessible approach using routine blood tests. The National Institutes of Health–funded investigation underscores an overlooked population that can be flagged before clinical events occur.

The investigators defined prediabetes as fasting blood glucose of 100–125 milligrams per deciliter. Subclinical myocardial injury was defined as hs-cTnI ≥6 nanograms per liter in men or ≥4 nanograms per liter in women. Subclinical cardiac stress was defined as NT-proBNP ≥125 picograms per milliliter. Hazard ratios were calculated to compare HF incidence based on biomarker status at baseline and changes over time.

Using data from the Systolic Blood Pressure Intervention Trial (SPRINT), the team analyzed 8,234 participants ages 50 and older (mean 68 years) without diagnosed diabetes (62.9% male, 37.1% female). Two analyses were performed: outcomes by baseline biomarker levels and outcomes by biomarker changes at 12 months. At baseline, 39.7% had prediabetes, 35.7% had subclinical injury, and 43.6% had subclinical stress, with a median follow-up of 3.2 years.

Participants with baseline prediabetes plus either subclinical injury or stress were overall 10 times more likely to experience HF. By comparison, those without prediabetes but with injury or stress had moderate risk increases (hazard ratios 3.28 and 3.78, respectively). Over time, individuals with prediabetes and a ≥25% rise in hs-cTnI or NT-proBNP were 3.05 and 2.39 times more likely to develop HF, compared with 2.60 and 1.66 among those without diabetes; prediabetes alone was not linked to risk change. The authors conclude that routine biomarker testing could help target preventive interventions in this group.

“We already know there’s a link between prediabetes and heart failure. But we wanted to see if additional factors, such as subclinical heart injury or stress, could elevate the risk of developing heart failure beyond prediabetes alone,” said Justin Basile Echouffo Tcheugui, M.D., Ph.D., associate professor of medicine at the Johns Hopkins University School of Medicine.

“Using heart failure biomarkers, we can identify and treat these patients who have a much higher risk of cardiovascular disease, but this also means we can look at biomarkers for other cardiovascular events. The prediabetes state is often overlooked in patients, but by defining vulnerable subpopulations, we can take preventive actions to care for patients before emergencies occur,” said Echouffo Tcheugui.

Related Links
Johns Hopkins Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.